Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.
Richly
H
H
West German Cancer Center, University of Essen, Germany.
Kupsch
P
P
Passage
K
K
Grubert
M
M
Hilger
R A
RA
Voigtmann
R
R
Schwartz
B
B
Brendel
E
E
Christensen
O
O
Haase
C G
CG
Strumberg
D
D
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use*; D018281:Cholangiocarcinoma / Q000188:drug therapy*; D004317:Doxorubicin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D000077157:Sorafenib
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D004317:Doxorubicin; D000077157:Sorafenib